MX2020007036A - Combinaciones de inhibidores ripk1 e ikk para la prevención o tratamiento de enfermedades inmunitarias. - Google Patents
Combinaciones de inhibidores ripk1 e ikk para la prevención o tratamiento de enfermedades inmunitarias.Info
- Publication number
- MX2020007036A MX2020007036A MX2020007036A MX2020007036A MX2020007036A MX 2020007036 A MX2020007036 A MX 2020007036A MX 2020007036 A MX2020007036 A MX 2020007036A MX 2020007036 A MX2020007036 A MX 2020007036A MX 2020007036 A MX2020007036 A MX 2020007036A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- ripk1
- ikk
- combinations
- treatment
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 239000003458 I kappa b kinase inhibitor Substances 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102100030011 Endoribonuclease Human genes 0.000 abstract 1
- 101710199605 Endoribonuclease Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere al tratamiento de enfermedades asociadas con una respuesta inmune desregulada, tales como trastornos autoinmunes, enfermedades inflamatorias o respuestas inmunes patológicas como efectos adversos de tratamientos médicos. En particular, la invención proporciona un uso combinado de inhibidores de la serina/treonina-proteína quinasa 1 que interactúan con el receptor (RIPK1) y los inhibidores de inhibidor de ?B (I?B) quinasa (IKK) en sujetos que padecen tales trastornos. La invención proporciona dichos compuestos inhibidores y sus combinaciones para su uso en aplicaciones médicas, así como composiciones farmacéuticas que comprenden los compuestos de la invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17205864.6A EP3494994A1 (en) | 2017-12-07 | 2017-12-07 | Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases |
| PCT/EP2018/084055 WO2019110832A1 (en) | 2017-12-07 | 2018-12-07 | Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007036A true MX2020007036A (es) | 2020-12-03 |
Family
ID=60629504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007036A MX2020007036A (es) | 2017-12-07 | 2018-12-07 | Combinaciones de inhibidores ripk1 e ikk para la prevención o tratamiento de enfermedades inmunitarias. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200383995A1 (es) |
| EP (2) | EP3494994A1 (es) |
| JP (1) | JP7527639B2 (es) |
| CN (1) | CN111670049A (es) |
| CA (1) | CA3103847A1 (es) |
| MX (1) | MX2020007036A (es) |
| WO (1) | WO2019110832A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021046515A1 (en) * | 2019-09-06 | 2021-03-11 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| IL291665B2 (en) | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| JP2023502514A (ja) | 2019-11-26 | 2023-01-24 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 疾患の処置のための受容体相互作用プロテインキナーゼｉの阻害剤 |
| EP4209213A1 (en) | 2022-01-05 | 2023-07-12 | Universität zu Köln | Signalling-pathway inhibitor combinations for use in the treatment of cancer diseases |
| EP4665334A1 (en) | 2023-02-17 | 2025-12-24 | Universität zu Köln | Triple kinase inhibition for the treatment of type i interferon response associated disorders |
| CN119064582B (zh) * | 2024-09-02 | 2025-05-27 | 南方医科大学南方医院 | RIPK1 O-GlcNAc糖基化抑制剂在制备增强肾细胞癌舒尼替尼敏感性药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL364111A1 (en) | 2001-02-01 | 2004-12-13 | Bristol-Myers Squibb Company | Methods of treating inflammatory and immune diseases using inhibitors of ikappab kinase (ikk) |
| US7592353B2 (en) * | 2006-06-06 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
| ES2555160B1 (es) * | 2014-06-24 | 2016-10-25 | Aptus Biotech, S.L. | Aptámeros específicos de TLR-4 y usos de los mismos |
| EP3017825A1 (en) * | 2014-11-06 | 2016-05-11 | Ludwig-Maximilians-Universität München | An inhibitor of the RIPK1-dependent necrosis pathway and a pharmaceutical composition comprising the same |
-
2017
- 2017-12-07 EP EP17205864.6A patent/EP3494994A1/en not_active Withdrawn
-
2018
- 2018-12-07 CA CA3103847A patent/CA3103847A1/en active Pending
- 2018-12-07 MX MX2020007036A patent/MX2020007036A/es unknown
- 2018-12-07 US US16/769,972 patent/US20200383995A1/en active Pending
- 2018-12-07 CN CN201880088634.3A patent/CN111670049A/zh active Pending
- 2018-12-07 JP JP2020531104A patent/JP7527639B2/ja active Active
- 2018-12-07 WO PCT/EP2018/084055 patent/WO2019110832A1/en not_active Ceased
- 2018-12-07 EP EP18826203.4A patent/EP3720493B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7527639B2 (ja) | 2024-08-05 |
| JP2021505611A (ja) | 2021-02-18 |
| EP3494994A1 (en) | 2019-06-12 |
| WO2019110832A1 (en) | 2019-06-13 |
| US20200383995A1 (en) | 2020-12-10 |
| EP3720493B1 (en) | 2024-07-24 |
| CA3103847A1 (en) | 2019-06-13 |
| EP3720493A1 (en) | 2020-10-14 |
| CN111670049A (zh) | 2020-09-15 |
| EP3720493C0 (en) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202502751B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
| EP4234551A3 (en) | Pyridazinones as parp7 inhibitors | |
| PH12021551455A1 (en) | Jak1 pathway inhibitors for the treatment of gastrointestinal disease | |
| MX2023009652A (es) | Inhibidores peptidicos de la acumulacion de alfa-sinucleina basados en estructuras. | |
| PH12016501107B1 (en) | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology | |
| MX373658B (es) | Derivado de acido 4-(4-(4-fenilureido-naftalen-1-il)oxi-piridin-2-il)amino-benzoico como inhibidor de quinasa p38. | |
| WO2016172134A3 (en) | Novel compounds | |
| PH12017501669A1 (en) | Alpha-cinnamide compounds and compositions as hdac8 inhibitors | |
| MY196186A (en) | Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor | |
| MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
| MX2020006614A (es) | Derivados de cromenopiridina como inhibidores de fosfatidilinositol fosfato cinasa,. | |
| WO2015200790A3 (en) | Compositions and methods to regulate renalase in the treatment of diseases and disorders | |
| MX371153B (es) | Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik). | |
| MX371152B (es) | Nuevos derivados de pirazolopirimidina como inhibidores de la cinasa inductora de nf-kb (nk). | |
| MX371150B (es) | NUEVOS DERIVADOS DE PIRAZOL EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK). | |
| WO2015106200A3 (en) | Dipeptides as inhibitors of human immunoproteasomes | |
| EP3720493C0 (en) | COMBINATIONS OF RIPK1 AND IKK INHIBITORS FOR THE PREVENTION OR TREATMENT OF IMMUNE DISEASES | |
| WO2020109233A3 (en) | Trmt2a inhibitors for use in the treatment of polyglutamine diseases | |
| WO2016028571A3 (en) | Dipeptidomimetics as inhibitors of human immunoproteasomes | |
| PH12019500464A1 (en) | An oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy | |
| EA201891687A1 (ru) | Новые замещённые производные цианиндолина в качестве nik- ингибиторов | |
| EA201990393A1 (ru) | Композиции и способы для ингибирования masp-3, применяемые в целях лечения различных заболеваний и расстройств | |
| HK1248601A1 (zh) | 作為激酶抑制劑的嘧啶衍生物及其治療應用 |